Jusoor — Shingrix Immunisation Programme

Enrolled

50

opt-in cohort

Dose 1 given

0

Series complete

0

Dose 2 overdue

0

recovery needed

Symptom follow-ups

0

post-vaccine

AI risk distribution

Enrolled patients by risk band

Risk segments

Enrolled by profile · click a slice

Series completion — trend

Cumulative Dose 1 vs complete

Risk stratification

By profile · click a bar

Dose status

Dose 1 coverage by centre

Eligibility mix

Priority patients — AI flagged

PHC cluster performance

PHC centre	Dose 1	Complete
Al Olaya, Riyadh	71%	66%
Al Naseem, Riyadh	64%	60%
Al Rawdah, Jeddah	62%	55%
Al Aziziyah, Makkah	58%	52%

Patient Registry · 50 enrolled

AI risk scored locally · click a row for the full record

Patient	File #	Age	Risk profile	Comorbidities	Allergy	Insurance	AI risk	Eligibility	Dose 1	Dose 2	Status	Physician

Morning Huddle

Monday, 22 June 2026 · Table round

PHC Cluster · Riyadh
Coordinator: Sarah Al-Ghamdi

10:00

Progress 0 / 0

Round queue · 0 patients

Select a patient from the round queue.

Open tasks

0

care-team to-do

Completed today

0

resolved

Care-team to-do list

Actions raised from the Morning Huddle land here, grouped by patient so the team doesn't forget — no duplicates.

🎯 Two-dose completion — finish every series

Shingrix is a two-dose vaccine — protection is incomplete until Dose 2, and that's where coverage leaks. This board chases every started patient to completion: schedule → remind (3 & 2 days) → recall.

Completion rate

0%

both doses / started

Dose 2 due

0

window open

Dose 2 overdue

0

recall now

Dose 1 only

0

to schedule

① Dose 1 given — schedule Dose 2

Only partially protected. Book the second dose now (2–6 months; 1–2 months if immunocompromised).

② Dose 2 window open — book & remind

The window is open — send the automatic 3-day and 2-day reminders before the appointment.

③ Dose 2 overdue — recall

Protection incomplete. Message: "no need to restart — one dose finishes it." Re-approach with the educator/physician.

Tele-consult queue · 0

Vaccine questions · post-vaccine symptoms · second dose

Select a consult to open the vaccine discussion and post-vaccine symptom review.

🇸🇦 Saudi Shingrix eligibility

✅ Adults 50+ — regardless of prior shingles or prior vaccine.

✅ Adults 18+ who are immunocompromised: cancer on chemotherapy, organ transplant, immunosuppressive medication, certain autoimmune & haematologic conditions, other causes of weakened immunity.

Dosing: 2 doses; second 2–6 months after first (1–2 months for some immunocompromised).

Send patient message

Patient — type name or file #

Arabic template

Arabic message (للمريض)

English (reference)

Message templates

Active caseload

50

enrolled · view

Sessions delivered

0

patients reached · view

Active goals

0

set · view

Education pending

0

to deliver · view

Log education session

Patient

Session type

Duration (min)

Notes

Set patient goal

Patient

Goal category

Specific goal (SMART)

Target date

Education progress tracker

Patient	Profile	Shingles risk	What to expect	Dose 2	Symptom care	Booking	Progress

Arabic WhatsApp bot — live simulator

Tap patient replies to walk every branch

💚

مساعد جسور للتطعيم

متصل الآن · ذكاء اصطناعي

Live bot stats · today

Conversations started1,184

Eligibility confirmed921

Registration links sent734

Caregiver numbers captured73

Symptom reports triaged58

💬

Bot intelligence

What the engine handles

Eligibility: 50+ for all · 18+ if immunocompromised

Auto-offers shorter 1–2 month Dose 2 to immunocompromised

Handles concerns (cost · pain · time · need) and offers booking

Promises 3-day & 2-day pre-visit reminders; chases Dose 2

Triages post-vaccine symptoms; escalates severe to nurse

Local knowledge base — what the bot can answer

Curated Shingrix Q&A served on-device · 🔒 no patient data leaves Saudi Arabia · an external LLM can optionally be linked in Settings for open-ended questions

Compose Arabic campaign

Target segment

Message (Arabic)

WhatsApp preview

Collected barriers — live

Captured by coordinators & the bot · the AI engine routes each one to a Care Task + tailored education (closes the dose-2 drop-off loop)

Why patients decline or delay

Mapped to WHO 5C model

🧠

AI counter-message

Auto-served Arabic

Safety fear · 31%

اللقاح آمن ومعتمد — أعراض بسيطة ليوم أو يومين فقط.

Complacency · 24%

Serve personal risk number + PHN testimonial.

Side-effect worry · 18%

Pre-warn sore arm is normal; offer symptom follow-up.

Dominant barrier by PHC cluster

PHC	Top barrier	Decline rate	Recommended fix
Al Olaya, Riyadh	Safety fear	12%	Doctor-endorsed safety message
Al Naseem, Riyadh	Complacency	16%	Risk calculator + testimonials
Al Rawdah, Jeddah	Side-effect worry	19%	Reactogenicity pre-warning
Al Aziziyah, Makkah	Access	21%	Pharmacy + workplace channels

Completion lift

+23%

vs baseline

Avg interval

3.4 mo

2–6 mo window

Dose-2 drop-off

14%

from 38%

RWE records

3,184

de-identified

System integrations (Saudi)

WhatsApp Business APIConnected

SehhatyConnected

NPHIES — coverage exchangePhase 0 demo

Raqeem — health platformPhase 1 pilot

MOH immunisation registryPhase 3

AI engine architecture

🖥 Local rule engine (default): eligibility & risk scoring run in the browser — transparent rules, no patient data leaves the device.

☁ External AI proxy (optional): for heavy generative work, set AI_ENGINE.mode='proxy' + a Cloudflare Worker endpoint in Settings; only de-identified features are sent, local stays the fallback. Mirrors the diabetic platform's ai-proxy-worker.js.

Co-publication pathway

Consented self-report → de-identification → dose-interval analytics → adherence cohort study → Medical Affairs co-publication. A clean Saudi real-world-evidence story with zero MOH-data dependency.